Cara Therapeutics, Inc. (CARA)

NASDAQ: CARA · IEX Real-Time Price · USD

0.278

+0.015 (5.67%)

At close: Jul 2, 2024, 4:00 PM

0.285

+0.007 (2.55%)

After-hours: Jul 2, 2024, 7:52 PM EDT

Cara Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2011
Revenue	20.97	41.87	23.03	135.08	19.89	Upgrade
Revenue Growth (YoY)	-49.92%	81.81%	-82.95%	579.28%	47.64%	Upgrade
Cost of Revenue	6.17	7.27	0	0	0	Upgrade
Gross Profit	14.79	34.6	23.03	135.08	19.89	Upgrade
Selling, General & Admin	27.78	30.26	29.41	21.85	17.75	Upgrade
Research & Development	108.51	91.88	82.7	107.85	113.82	Upgrade
Operating Expenses	136.29	122.14	112.11	129.7	131.57	Upgrade
Operating Income	-121.5	-87.54	-89.08	5.39	-111.68	Upgrade
Interest Expense / Income	0.6	0	0	0	0	Upgrade
Other Expense / Income	-3.59	-2.06	-0.64	-2.33	-4.49	Upgrade
Pretax Income	-118.51	-85.47	-88.44	7.72	-107.19	Upgrade
Income Tax	0	0	0	-0.69	-0.82	Upgrade
Net Income	-118.51	-85.47	-88.44	8.41	-106.37	Upgrade
Shares Outstanding (Basic)	54	54	51	47	43	Upgrade
Shares Outstanding (Diluted)	54	54	51	48	43	Upgrade
Shares Change	0.92%	5.79%	5.85%	12.29%	18.88%	Upgrade
EPS (Basic)	-2.19	-1.59	-1.74	0.18	-2.49	Upgrade
EPS (Diluted)	-2.19	-1.59	-1.74	0.18	-2.49	Upgrade
Free Cash Flow	-94.45	-78.77	-60.06	-5.84	-109.24	Upgrade
Free Cash Flow Per Share	-1.74	-1.47	-1.18	-0.12	-2.56	Upgrade
Gross Margin	70.56%	82.65%	100.00%	100.00%	100.00%	Upgrade
Operating Margin	-579.43%	-209.08%	-386.85%	3.99%	-561.60%	Upgrade
Profit Margin	-565.21%	-204.16%	-384.06%	6.23%	-534.91%	Upgrade
Free Cash Flow Margin	-450.46%	-188.15%	-260.80%	-4.32%	-549.35%	Upgrade
Effective Tax Rate	-	-	-	-8.95%	-	Upgrade
EBITDA	-115.58	-83.8	-86.89	8.73	-106.39	Upgrade
EBITDA Margin	-551.20%	-200.17%	-377.31%	6.47%	-535.00%	Upgrade
Depreciation & Amortization	2.33	1.67	1.55	1.02	0.8	Upgrade
EBIT	-117.91	-85.47	-88.44	7.72	-107.19	Upgrade
EBIT Margin	-562.33%	-204.16%	-384.06%	5.71%	-539.02%	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).